持田製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2024/02/29 | 3,295 | 3,295 | 3,255 | 3,270 | -20 | -0.6% | 40,300 |
2024/02/28 | 3,265 | 3,300 | 3,265 | 3,290 | +10 | +0.3% | 28,100 |
2024/02/27 | 3,230 | 3,300 | 3,230 | 3,280 | +40 | +1.2% | 46,100 |
2024/02/26 | 3,235 | 3,240 | 3,215 | 3,240 | +40 | +1.3% | 35,500 |
2024/02/22 | 3,180 | 3,205 | 3,170 | 3,200 | +20 | +0.6% | 35,200 |
2024/02/21 | 3,190 | 3,210 | 3,160 | 3,180 | -10 | -0.3% | 27,600 |
2024/02/20 | 3,175 | 3,210 | 3,175 | 3,190 | +15 | +0.5% | 22,600 |
2024/02/19 | 3,120 | 3,175 | 3,120 | 3,175 | +55 | +1.8% | 20,600 |
2024/02/16 | 3,105 | 3,145 | 3,095 | 3,120 | +50 | +1.6% | 44,800 |
2024/02/15 | 3,200 | 3,200 | 3,055 | 3,070 | -105 | -3.3% | 107,200 |
2024/02/14 | 3,255 | 3,260 | 3,170 | 3,175 | -65 | -2% | 47,400 |
2024/02/13 | 3,245 | 3,265 | 3,210 | 3,240 | +15 | +0.5% | 62,000 |
2024/02/09 | 3,205 | 3,230 | 3,195 | 3,225 | +10 | +0.3% | 26,900 |
2024/02/08 | 3,170 | 3,240 | 3,150 | 3,215 | +45 | +1.4% | 54,900 |
2024/02/07 | 3,165 | 3,185 | 3,145 | 3,170 | -5 | -0.2% | 49,200 |
2024/02/06 | 3,235 | 3,245 | 3,170 | 3,175 | -40 | -1.2% | 84,300 |
2024/02/05 | 3,335 | 3,380 | 3,145 | 3,215 | -120 | -3.6% | 136,500 |
2024/02/02 | 3,355 | 3,365 | 3,330 | 3,335 | +15 | +0.5% | 31,900 |
2024/02/01 | 3,300 | 3,335 | 3,280 | 3,320 | -30 | -0.9% | 36,200 |
2024/01/31 | 3,305 | 3,350 | 3,290 | 3,350 | +35 | +1.1% | 25,400 |
2024/01/30 | 3,365 | 3,365 | 3,310 | 3,315 | -20 | -0.6% | 30,200 |
2024/01/29 | 3,320 | 3,345 | 3,320 | 3,335 | +15 | +0.5% | 25,800 |
2024/01/26 | 3,310 | 3,345 | 3,290 | 3,320 | +10 | +0.3% | 37,600 |
2024/01/25 | 3,280 | 3,310 | 3,275 | 3,310 | +25 | +0.8% | 29,400 |
2024/01/24 | 3,300 | 3,315 | 3,260 | 3,285 | -30 | -0.9% | 30,600 |
2024/01/23 | 3,325 | 3,360 | 3,315 | 3,315 | -10 | -0.3% | 29,100 |
2024/01/22 | 3,350 | 3,360 | 3,320 | 3,325 | -5 | -0.2% | 19,700 |
2024/01/19 | 3,325 | 3,345 | 3,320 | 3,330 | +5 | +0.2% | 19,300 |
2024/01/18 | 3,350 | 3,350 | 3,320 | 3,325 | -20 | -0.6% | 25,100 |
2024/01/17 | 3,380 | 3,410 | 3,345 | 3,345 | -35 | -1% | 36,300 |
2024/01/16 | 3,420 | 3,430 | 3,370 | 3,380 | -30 | -0.9% | 22,300 |
2024/01/15 | 3,380 | 3,420 | 3,370 | 3,410 | +50 | +1.5% | 23,500 |
2024/01/12 | 3,415 | 3,415 | 3,350 | 3,360 | -40 | -1.2% | 24,700 |
2024/01/11 | 3,400 | 3,410 | 3,375 | 3,400 | +10 | +0.3% | 31,100 |
2024/01/10 | 3,375 | 3,405 | 3,330 | 3,390 | +35 | +1% | 38,200 |
2024/01/09 | 3,310 | 3,365 | 3,310 | 3,355 | +45 | +1.4% | 26,800 |
2024/01/05 | 3,330 | 3,335 | 3,295 | 3,310 | -15 | -0.5% | 21,000 |
2024/01/04 | 3,270 | 3,325 | 3,230 | 3,325 | +55 | +1.7% | 33,600 |
2023/12/29 | 3,295 | 3,295 | 3,260 | 3,270 | -15 | -0.5% | 15,800 |
2023/12/28 | 3,290 | 3,290 | 3,250 | 3,285 | +15 | +0.5% | 17,400 |
2023/12/27 | 3,225 | 3,275 | 3,225 | 3,270 | +25 | +0.8% | 29,100 |
2023/12/26 | 3,255 | 3,270 | 3,235 | 3,245 | +5 | +0.2% | 29,400 |
2023/12/25 | 3,260 | 3,270 | 3,230 | 3,240 | -45 | -1.4% | 21,000 |
2023/12/22 | 3,265 | 3,290 | 3,260 | 3,285 | +45 | +1.4% | 18,100 |
2023/12/21 | 3,245 | 3,260 | 3,240 | 3,240 | -15 | -0.5% | 18,400 |
2023/12/20 | 3,225 | 3,270 | 3,225 | 3,255 | +25 | +0.8% | 21,100 |
2023/12/19 | 3,265 | 3,270 | 3,215 | 3,230 | -30 | -0.9% | 24,800 |
2023/12/18 | 3,245 | 3,265 | 3,215 | 3,260 | +5 | +0.2% | 26,200 |
2023/12/15 | 3,330 | 3,330 | 3,255 | 3,255 | -55 | -1.7% | 44,000 |
2023/12/14 | 3,335 | 3,335 | 3,290 | 3,310 | +10 | +0.3% | 21,600 |
301~
350
件表示中 / 3705件
類似銘柄と比較する
現在ご覧いただいている「持田薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
持田薬 | 297,600円 | +5.1% | -7.0% | 2.69% | 19.54倍 | 0.81倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
ジーエヌアイ | 297,100円 | +21.7% | +999.9% | 0.00% | 12.45倍 | 4.12倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
ゼリア新薬 | 213,700円 | +3.1% | -6.5% | 2.25% | 9.92倍 | 1.05倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
杏林製薬 | 146,000円 | -2.4% | -52.3% | 3.90% | 17.47倍 | 0.62倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
栄研化 | 200,000円 | +4.1% | -3.1% | 2.90% | 17.54倍 | 1.53倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム